Sage Journals: Discover world-class research

Abstract

Objective. To assess the safety, pharmacokinetics (PKs), and blood pressure (BP)-lowering efficacy of telmisartan in pediatric (6 to <18 years) patients with hypertension. Study design. Patients with diagnosed hypertension were randomized to 4 weeks of treatment with placebo, or with 1 of 2 nominal telmisartan dose levels (1 mg/kg/d or 2 mg/kg/d). The primary end point was change in seated systolic BP (SBP) from baseline to study end. Results. A total of 77 patients were randomized and received at least 1 dose of study medication (placebo, n = 16; low-dose telmisartan, n = 30; high-dose telmisartan, n = 31). Adjusted mean changes (standard errors) in SBP from baseline to study end were −6 (2.4), −14 (1.7), and −9.7 (1.7) mm Hg, respectively, in the placebo, high-dose telmisartan, and low-dose telmisartan groups. Conclusions. Telmisartan may be an appropriate therapy for treatment of pediatric hypertension, although more extensive studies are required in patients younger than age 12.

Keywords

angiotensin receptor blocker blood pressure pediatric hypertension pediatric pharmacokinetics telmisartan

Get full access to this article

View all access options for this article.

References

The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics . 2004;114(2 suppl, 4th report):555-576.

Chobanian AV , Bakris GL , Black HR , et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.

Ogden CL , Flegal KM , Carroll MD , Johnson CL Prevalence and trends in overweight among US children and adolescents, 1999-2000 . JAMA. 2002;288:1728-1732.

Sorof J. , Daniels S. Obesity hypertension in children: a problem of epidemic proportions. Hypertension. 2002;40: 441-447.

Sorof JM , Lai D. , Turner J. , Poffenbarger T. , Portman RJ Overweight, ethnicity, and the prevalence of hypertension in school-aged children . Pediatrics. 2004;113(3, pt 1): 475-482.

Sinaiko AR , Steinberger J. , Moran A. , Prineas RJ , Jacobs DR Jr. Relation of insulin resistance to blood pressure in childhood. J Hypertens. 2002;20:509-517.

Sorof JM Prevalence and consequence of systolic hypertension in children. Am J Hypertens. 2002;15(2, pt 2): 57S-60S.

Lande MB , Adams H. , Falkner B. , et al. Parental assessments of internalizing and externalizing behavior and executive function in children with primary hypertension. J Pediatr. 2009;154:207-212.

Lande MB , Kaczorowski JM , Auinger P. , Schwartz GJ , Weitzman M. Elevated blood pressure and decreased cognitive function among school-age children and adolescents in the United States. J Pediatr. 2003;143:720-724.

10.

Littlejohn T. , Mroczek W. , Marbury T. , VanderMaelen CP , Dubiel RF A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. Can J Cardiol. 2000;16:1123-1132.

11.

Mallion J. , Siche J. , Lacourciere Y. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens. 1999;13:657-664.

12.

Sharpe M. , Jarvis B. , Goa KL Telmisartan: a review of its use in hypertension. Drugs. 2001;61:1501-1529.

13.

Benjamin DK Jr , Smith PB , Jadhav P. , et al. Pediatric antihypertensive trial failures: analysis of end points and dose range. Hypertension. 2008;51:834-840.

Safety,Efficacy,and Pharmacokinetics of Telmisartan in Pediatric Patients With Hypertension

Abstract

Keywords

Get full access to this article

References